Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2017

01-04-2017 | Editorial

LRRK2 Expression in the Enteric Nervous System: ENSuring Its Significance

Author: Pascal Derkinderen

Published in: Digestive Diseases and Sciences | Issue 4/2017

Login to get access

Excerpt

The hypothesis that the gut is a second brain arose in the early 1900s, when it was discovered that enteric nervous system (ENS) control of intestinal motility and secretion was largely independent of influences from the central nervous system (CNS). The ENS contains as many neurons as the spinal cord; the functional and chemical diversity of enteric neurons closely resembles that of the CNS. The ENS controls gut motility and secretion via local reflexes regulated by the liberation of specific neuromediators synthesized by functionally defined enteric neurons [1]. For example, among the most common neurotransmitters in the ENS, vasoactive intestinal peptide (VIP) and nitric oxide are often expressed in inhibitory muscle motoneurons, whereas acetylcholine and substance P are expressed in excitatory motoneurons. Aside from its well-recognized influences on gastrointestinal motility disorders, it has become evident over the last 20 years that the ENS is also substantially involved in Parkinson’s and Crohn’s diseases. At some point in the disease course, gastrointestinal symptoms occur in almost every Parkinson’s disease (PD) patient, clinical observations supported by postmortem studies that demonstrated the presence of alpha-synuclein inclusions, the defining neuropathological hallmark of the disease, in the ENS of almost all Parkinsonian subjects [2]. In Crohn’s disease, a number of studies consistently reported quantitative and qualitative changes in the neurochemical composition of enteric neurons in the small intestine and in the rectum [3, 4]. Remarkably, genome-wide association studies identified leucine-rich repeat kinase 2 (LRRK2), the most common gene implicated in the pathogenesis of autosomal dominant PD, as one of the susceptibility genes for Crohn’s disease [5]. These genetic data have been supported by a recent Taiwanese epidemiological study, which reported an increased risk of PD among individuals with Crohn’s disease [6]. …
Literature
1.
go back to reference Schemann M, Neunlist M. The human enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 1):55–59.CrossRefPubMed Schemann M, Neunlist M. The human enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 1):55–59.CrossRefPubMed
2.
go back to reference Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology. 2011;77:1761–1767.CrossRefPubMed Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology. 2011;77:1761–1767.CrossRefPubMed
3.
go back to reference Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20:1009–1016.CrossRefPubMed Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20:1009–1016.CrossRefPubMed
4.
go back to reference Schneider J, Jehle EC, Starlinger MJ, et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn’s disease. Neurogastroenterol Motil. 2001;13:255–264.CrossRefPubMed Schneider J, Jehle EC, Starlinger MJ, et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn’s disease. Neurogastroenterol Motil. 2001;13:255–264.CrossRefPubMed
5.
go back to reference Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.CrossRefPubMedPubMedCentral Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.CrossRefPubMedPubMedCentral
6.
go back to reference Lin J-C, Lin C-S, Hsu C-W, Lin C-L, Kao C-H. Association between Parkinson’s disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm Bowel Dis. 2016;22:1049–1055.CrossRefPubMed Lin J-C, Lin C-S, Hsu C-W, Lin C-L, Kao C-H. Association between Parkinson’s disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm Bowel Dis. 2016;22:1049–1055.CrossRefPubMed
7.
go back to reference Maekawa T, Shimayama H, Tsushima H, et al. LRRK2: an emerging new molecule in the enteric neuronal system that quantitatively regulates neuronal peptides and IgA in the gut. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-017-4476-3. Maekawa T, Shimayama H, Tsushima H, et al. LRRK2: an emerging new molecule in the enteric neuronal system that quantitatively regulates neuronal peptides and IgA in the gut. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-017-4476-3.
8.
go back to reference Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469–1480.e12.CrossRefPubMed Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469–1480.e12.CrossRefPubMed
9.
go back to reference Yue M, Hinkle KM, Davies P, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172–195.CrossRefPubMedPubMedCentral Yue M, Hinkle KM, Davies P, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172–195.CrossRefPubMedPubMedCentral
Metadata
Title
LRRK2 Expression in the Enteric Nervous System: ENSuring Its Significance
Author
Pascal Derkinderen
Publication date
01-04-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4500-7

Other articles of this Issue 4/2017

Digestive Diseases and Sciences 4/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.